PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN.

NPJ Precis Oncol · 2021 · PMC8289936 · PMID 34282258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, clinical studies have reported that patients with melanoma carrying BRAF mutation and PTEN inactivation showed a trend for shorter median progression-free survival (PFS) on BRAF inhibitor-targeted therapy than patients with melanoma having wild-type PTEN 19 , 20 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.